iCardiac Moves Into New Corporate Headquarters

University of Rochester Spin-Off Company Now Positioned for Further Expansion

ROCHESTER, N.Y. – October 17, 2006 – iCardiac Technologies, Inc., a company formed earlier this year to commercialize leading cardiac safety technologies developed at the University of Rochester Medical Center, announced today that it has moved to a new office facility due to the continued expansion of its operations. The new office of iCardiac Technologies is located at 150 Allens Creek Road in the Town of Brighton.

The new offices of iCardiac Technologies house an ECG core laboratory, as well as software development, project management and other business functions. The ECG laboratory, under an exclusive technology license agreement with the University of Rochester, will analyze ECG data from clinical trials using unique and proprietary technology and biomarkers to enable pharmaceutical companies to more effectively determine whether a drug poses cardiac risks.

“We are pleased to expand our operations in Rochester,” said Alex Zapesochny, iCardiac’s President and Chief Operating Officer. “Our new offices allow us to meet our immediate staffing goals, as well as flexible expansion options for future growth.”

About iCardiac Technologies, Inc.

iCardiac Technologies, Inc., headquartered in Rochester, N.Y., is a leading provider of advanced cardiac safety analysis technologies. The company evolved from research carried out at the Heart Research Follow-up Program at the University of Rochester. The company’s technology provides more rigorous characterization of the cardiac safety profiles of in-development and on-market drugs. This allows iCardiac’s customers to both accelerate drug development as well as bring compounds forward in clinical trials with more confidence about their cardiac safety. Additionally, the company’s core technology has applications in ECG-based cardiac diagnostics and medical devices. For more information on iCardiac Technologies, visit www.icardiac.com.

# # #